Controversial, self-acclaimed relationship expert, Blessing Okoro, popularly known as Blessing CEO, has confirmed dating ...

Blessing CEO, an online relationship therapist, has come forward with her relationship with IVD, whose ex-wife Bimbo died in ...

Controversial social media personality and self-acclaimed therapist, Blessing Okoro, aka Blessing CEO, has raised a lot of ...

Anbio Biotechnology seeks IPO funding to expand in the IVD market. Discover why NNNN stock’s potential is tempered by ...

12月30日，新华医疗（600587.SH）发布公告称，拟以1.66亿元的价格收购武汉中帜生物科技股份有限公司（简称“中帜生物”，证券代码：836834）36.19%股权。此次股权收购事项完成后，新华医疗将成为中帜生物的控股股东，并对中帜生物董事会进 ...

Controversial self-acclaimed relationship expert Blessing Okoro, best known as Blessing CEO, has revealed that she is in a ...

The global IVD contract manufacturing market is on a strong growth trajectory, with a projected market valuation of USD 14.7 billion in 2024, anticipated to increase to an impressive USD 46 billion by ...

12月30日，安徽省发布《关于开展2024年体外诊断试剂省际联盟集中带量采购申报信息公开的通知》，这场历时近3个月，涉及全国28省，IVD史上最大规模的一场集采终于公布结果。 IVD细分赛道众多且分散，免疫诊断是其中最大的细分市场，向来是兵家必争之地 ...

NEW YORK – Anbio Biotechnology filed this week a preliminary prospectus for an initial public offering on the Nasdaq exchange of 1.6 million shares at an anticipated offering price in the range of $5 ...

在中国IVD（体外诊断）行业经历了一段低迷时期后，丹娜（天津）生物科技股份有限公司成功取得IPO审核通过的消息无疑成为市场的一剂强心针。本周，审议会议中仅有一家企业通过审核，而丹娜生物正是这唯一的幸存者，标志着IVD行业正式打破零上市的尴尬局面，期待其带动行业的复苏与发展。 丹娜生物的IPO保荐机构为招商证券，法律顾问为中伦，计划募集资金高达3.00亿元人民币。该公司专注于侵袭性真菌病及其他病原微 ...

IVD企业的资本寒冬还未破冰。 12月20日据披露，北京证券交易所上市委员会定于2024年12月27日上午9时召开2024年第26次审议会议。审议的发行人是丹娜生物。 公开信息显示，丹娜（天津）生物科技 ...